FDA requires additional safety data before approving HBV vaccine Heplisav
February 25, 2013
The FDA will not approve hepatitis B vaccine Heplisav for its proposed indication without further safety data, according to a press release.
The drug (Dynavax) is a recombinant vaccine consisting of hepatitis B surface antigen and a Toll-like receptor 9 agonist developed to increase immune response. The company had sought approval for its use in adult patients aged 18 to 70 years.
Full Story »
Chronic acetaminophen exposure worsened outcomes for pediatric acute liver failure
February 25, 2013
Patients with pediatric acute liver failure had worse outcomes when exposed to chronic acetaminophen compared with those with single-dose exposure in a recent study.
More »
Fibromyalgia pain treatment moves to ‘high-definition’
February 25, 2013
More precise brain stimulation credited with less perceived pain.
High-definition transcranial direct current stimulation was well tolerated and produced a significant reduction in overall perceived pain in patients with fibromyalgia, according to recent study results.
Read more.
More »
Fibromyalgia pain treatment moves to ‘high-definition’
February 25, 2013
More precise brain stimulation credited with less perceived pain.
High-definition transcranial direct current stimulation was well tolerated and produced a significant reduction in overall perceived pain in patients with fibromyalgia, according to recent study results.
Read more.
No comments:
Post a Comment